Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years
Few weeks into its launch, Novo Nordisk's new obesity treatment Wegovy is in high demand in the US, especially compared with the older drug Saxenda. Overall, Novo Nordisk's obesity business has had a strong second quarter, according to report.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk's new obesity drug Wegovy certainly seems to have gotten off to a great start in the US following its approval from the US Food and Drug Administration (FDA) in early June.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance for the rest of the year
For subscribers
.jpg)
.jpg&w=384&q=75)
